Bristol-Myers files Rx-to-OTC switch NDA for Vagistat-1; company reassigns ad agencies.
This article was originally published in The Tan Sheet
BRISTOL-MYERS SEEKING OTC STATUS FOR VAGISTAT-1, a single-dose yeast infection drug, the firm noted in its recently released annual report. The company has submitted a supplemental NDA for the product. Vagistat-1 was approved for OTC marketing in the U.K. in January 1994 ("The Tan Sheet" Feb. 21, 1994, p. 6), but has not yet been introduced there.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC